Abstract
Hematopoietic stem cell transplantation is an effective method for treatment of hematologic malignancies. Due to the use of immunosuppressive agents and a long time of immune restoration after transplantation, the incidence of virus infection is high. Epstein-Barr virus (EBV) infection is a common viral infection after transplantation. In spite of the low incidence of post transplantation lymphoproliferative disorder (PTLD) caused by EBV, this disease is characte-rized by rapid progression and high mortality. T lymphocytes play an important role in anti-viral immunity, and the cellular immune therapy based on virus-specific cytotoxic T lymphocyte (CTL) is safe and efficient. This review presents the domestic and foreign advances in cellular immune treatment against EBV infection, and explores the clinical application prospects as well as problems.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
